Less Ads, More Data, More Tools Register for FREE

Pin to quick picksTILS.L Regulatory News (TILS)

  • There is currently no data for TILS

PRG Nutraceuticals UK Launch

1 Oct 2009 10:34

RNS Number : 0408A
ReGen Therapeutics PLC
01 October 2009
 



1 October 2009

For immediate release

ReGen Announces PRG Nutraceuticals Limited UK Launch

ReGen Therapeutics Plc ('ReGen' or the 'Company') is pleased to announce that it has been notified by PRG Nutraceuticals Limited that it has launched Colostrinin™* as 'MemoryAid' in the UK.

Announcing the launch, PRG Managing Director Dr Peter Garrod said:-

"Every day we hear more evidence of how the population faces a terrible future as our brains become increasingly affected by conditions associated with getting old. MemoryAid contains a complex that we believe will help people to fight the onset of the problems that result from our brains undergoing the normal ageing process. Many years of research into the complex has shown that it promotes antioxidant activity, can reduce the toxicity of beta amyloid and protects the brain against the damaging effects of free radicals, all of which manifest themselves in the problems that occur as our brains naturally age. The complex has also been shown to increase the average lifespan of living cells and reduces premature ageing, which will also benefit consumers.

MemoryAid is targeted at a wide spectrum of people, both the older community, who may already be noticing that their brains are not functioning in the manner they are normally accustomed to, and at younger adults, who just want to protect themselves against memory deterioration in the future.

We are very excited by the benefits of MemoryAid and believe that it has a bright future on everyone's breakfast table."

MemoryAid is available on the internet at www.memoryaid.com or by contacting PRG on 01580 891349 or mobile 07785 740421.  

MemoryAid

Support for healthy brain ageing

Maintains normal mental function and supports healthy brain ageing.

Increases the average lifespan of living cells.

Reduces the aggregation and toxicity of beta amyloid, a feature of neurodegenerative conditions.

Protects the brain against the damaging effects of many free radicals

*Colostrinin™ is a proline-rich polypeptide complex that maintains normal mental function and supports healthy brain ageing.

For further information:

Dr Peter Garrod

PRG Nutraceuticals Ltd

Tel. 01580 891349 / 07785 740421

Percy Lomax ReGen Therapeutics Plc Tel No 020 7153 4920

Roland Cornish/Felicity Geidt Beaumont Cornish Limited Tel No 020 7628 3396

Nick Bealer/David Scott Alexander David Tel No 020 7448 9820 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
NRAGCBDGIDGGGCB
Date   Source Headline
21st Apr 20204:40 pmRNSSecond Price Monitoring Extn
21st Apr 20204:36 pmRNSPrice Monitoring Extension
21st Apr 20207:00 amRNSNotice of GM
16th Apr 20209:05 amRNSSecond Price Monitoring Extn
16th Apr 20209:00 amRNSPrice Monitoring Extension
15th Apr 20204:31 pmRNSFurther Re: Block Listing Application
15th Apr 202011:05 amRNSSecond Price Monitoring Extn
15th Apr 202011:00 amRNSPrice Monitoring Extension
15th Apr 20207:00 amRNSBlock Listing Application
15th Apr 20207:00 amRNSIssue of Equity
14th Apr 20204:41 pmRNSSecond Price Monitoring Extn
14th Apr 20204:37 pmRNSPrice Monitoring Extension
14th Apr 202011:06 amRNSSecond Price Monitoring Extn
14th Apr 202011:01 amRNSPrice Monitoring Extension
9th Apr 20207:00 amRNSTiziana Develops Treatment For COVID-19 Patients
16th Mar 20205:21 pmRNSClosing of Offer
12th Mar 20207:00 amRNSTiziana U.S. Follow-On Offering of $10 million
11th Mar 20207:00 amRNSTZLS-501 / COVID-19
20th Feb 202010:30 amRNSResult of GM
17th Feb 20207:00 amRNSProposed U.S. Public Offering of ADSs
4th Feb 202012:00 pmRNSDirector/PDMR Shareholding
3rd Feb 20207:00 amRNSNotice of GM
23rd Jan 20207:00 amRNSFiling of SEC Form F-3
21st Jan 20202:45 pmRNSDirector Appointment
14th Jan 202011:00 amRNSDirector/PDMR Shareholding
13th Jan 20207:00 amRNSProposed Cancellation from AIM
9th Jan 20207:00 amRNSFurther re: Foralumab Phase 1 Trial
2nd Jan 20203:00 pmRNSDirector/PDMR Shareholding
4th Dec 20197:00 amRNSForalumab Phase 1 Trial
20th Nov 20197:00 amRNSIssue of Equity and Directorate Change
1st Nov 20197:00 amRNSIssue of CLN
30th Oct 201910:31 amRNSChange to ADS ratio
30th Sep 20197:00 amRNSHalf-year Report
16th Sep 20197:00 amRNSFurther re: Update on IND Application
10th Sep 20197:00 amRNSPhase 1 Clinical Data
4th Sep 20197:00 amRNSPhase 2a Clinical Data
21st Aug 20194:40 pmRNSSecond Price Monitoring Extn
21st Aug 20194:35 pmRNSPrice Monitoring Extension
6th Aug 20197:00 amRNSProposed U.S. Public Offering
22nd Jul 20197:00 amRNSPhase 2a Clinical Data
1st Jul 20197:00 amRNSTeplizumab Article
28th Jun 20194:40 pmRNSSecond Price Monitoring Extn
28th Jun 20194:35 pmRNSPrice Monitoring Extension
28th Jun 201910:54 amRNSChange of Adviser
25th Jun 20197:00 amRNSDirector/PDMR Shareholding
24th Jun 20197:00 amRNSArticle on Clinical Activity of OKT3
11th Jun 20197:00 amRNSDirector/PDMR Shareholding
7th Jun 20199:44 amRNSDirector/PDMR Shareholding
3rd Jun 20197:00 amRNSPDMR Dealings
31st May 201911:05 amRNSResult of AGM

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.